Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary

Adaptive Biotechnologies

29/07/2026 23:45

Adaptive Biotechnologies Corp ADPT.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -17 cents.  The mean expectation of eight analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -15 cents to -11 cents per share.
Revenue rose 21.5% to $71.55 million from a year ago; analysts expected $65.89 million. 
Adaptive Biotechnologies Corp's reported EPS for the quarter was a loss of 25 cents​.
The company reported a quarterly loss of $39.79 million.
Adaptive Biotechnologies Corp shares had risen by 5.0% this quarter and gained 38.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $21.00, about 7.2% below its last closing price of $22.52
This summary was machine generated from LSEG data July 29 at 10:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.13
-0.10
Beat
Mar. 31 2026 
-0.16
-0.12
Beat
Dec. 31 2025 
-0.18
-0.09
Beat
Sep. 30 2025 
-0.15
0.06
Beat